3
Announcements
Trials
Browse
Landscape
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Thoracic Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Neoplasms by Site
1
Multiple Chronic Conditions
1
Lung Neoplasms
1
Lung Diseases
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Interventions
Carboplatin
49
Pemetrexed
38
Cisplatin
34
Radiotherapy
32
Docetaxel
31
Gemcitabine
25
Paclitaxel
24
Nivolumab
18
pembrolizumab
15
Etoposide
15
Radiosurgery
13
Erlotinib Hydrochloride
11
Bevacizumab
11
Magnetic Resonance Spectroscopy
10
Vinorelbine
9
Radiation
9
Cyclophosphamide
7
Gefitinib
6
Fluorodeoxyglucose F18
6
Celecoxib
6
durvalumab
5
atezolizumab
5
Oxaliplatin
5
Irinotecan
5
Immunoglobulin G
5
Drug Therapy
5
Disulfides
5
Dexamethasone
5
Chemotherapy, Adjuvant
5
vandetanib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Lung Neoplasms
×
Patient Reported Outcome Measures
×
Clear all
NCT03053297
2018-02-08
PANORAMA
AstraZeneca
Terminated
89 enrolled